A Phase I/IIa, Open-label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma

Trial Profile

A Phase I/IIa, Open-label Bridging Safety and Pharmacodynamic Study of a New Formulation of 6 Month Extended Dosing With AGI - 101H Vaccine in the Treatment of Patients With Advanced Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs AGI 101H (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors AGIRx
  • Most Recent Events

    • 21 Apr 2016 Status changed from recruiting to discontinued due to problems in funding.
    • 16 Jan 2013 Treatment table added.
    • 15 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top